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Prevalence of GvHD
100 days (n 5 37*) 1 yr (n 5 32*) Latest F/U (n 5 18*)
Donor type Related Unrelated Related Unrelated Related Unrelated
Grade 2-4
AGvHD
4/16 (25%)2/21 (10%)1/15 (7%) 1/17 (6%)
Extensive
CGvHD
2/15 (13%)2/17 (12%) 3/8 (38%) 0/10 (0%)a
*n 5 Number of patients alive at day 100, alive at 1 yr and alive at
latest F/U which is longer than 1 yr after HSCT.
aFor related vs. unrelated, Fisher’s exact p 5 0.069. All other com-
parisons not significant with p . 0.1.
Poster Session I 77Twelve patients received a matched unrelated donor transplant, and
13 received a matched related donor transplant. Conditioning in-
cluded 1 of these 3 regimens: Busulfan, Fludarabine, and Alemtuza-
mab or rATG (N5 19); Busulfan, Cyclophospamide and ATG (N
5 2); or Cyclophosphamide and rATG (N5 4). Percent donor en-
graftment in the CD31 subset and whole blood chimerism
(WhBCh) was determined using short tandem repeats. Testing
started around day 130, and it was repeated every 2–4 weeks until
stable CD31 and WhBCh was achieved. Median follow up for liv-
ing patients was 16 mos (4–62 mos).
All patients initially engrafted. We observed 6 chimerism patterns
as shown in Table 1. Seventeen patients (68%) remained mixed chi-
mera for the duration of follow-up. A majority of patients (71%)
with mixed chimerism had either very low (\20%) or fluctuating
CD31 cell chimerism. One of four patients with declining
WhBCh, discordant with slowly increasing CD31 chimerism, de-
veloped late graft failure at 8 months post transplant, and underwent
a 2nd transplant. Both patients with a precipitous decline in CD31
and WhBCh rejected their grafts by 2 months post transplant. This
was the only pattern predictive of graft rejection. Low percentage or
fluctuations in donor CD31 chimerism, in light of stable WhBCh,
were not predictive of graft rejection or clinical outcome.207
OCCURRENCE OF GRAFT VERSUS HOST DISEASE AFTER HEMATOPOI-
ETIC STEM CELL TRANSPLANT UTILIZING REDUCED INTENSITY CONDI-
TIONING IN PEDIATRIC PATIENTS
Danner-Koptik, K.1, Fu, J.3, Dilley, K.J.1,2. 1Children’s Memorial Hos-
pital, Chicago, IL; 2Northwestern University, Chicago, IL; 3The Ohio
State University, Columbus, OH.
Background: Reduced intensity conditioning (RIC) regimens
are used as an alternative to traditional myeloablative conditioning
(TMC) for allogeneic hematopoietic stem cell transplant (HSCT)
in children. The main rationale is to allow tumor kill while decreas-
ing the degree of toxicity due to conditioning regimen. Objective:
To examine the occurrence of acute (A) and chronic (C) GvHD in
pediatric patients who received a RIC HSCT. Methods: Medical
record review of all patients who received a RIC HSCT from
2000 to the present at a single institution. Patients who ever re-
ceived a TMC HSCT or who had .1 RIC HSCT were excluded.
AGvHD data was collected at 100 days and 1 year; CGvHD was ex-
amined at 1 yr and latest follow-up (F/U). Results: Since 2000, 86
pediatric patients have undergone RIC HSCT for both malignant
(55%) and non-malignant (45%) diseases. 57% were male. All pa-
tients received a common backbone for conditioning including flu-
darabine and busulfan, plus or minus ATG or extracorporeal
photopheresis. At analysis, 27 patients were excluded for having re-
ceived a TMC HSCT and 15 more were excluded for .1 RIC
HSCT, with 44 patients who received a single RIC HCST included
in all further analyses. 17/44 (39%) transplants had related donor
peripheral blood stem cells as a donor source (related), which are
subsequently compared to all other sources (unrelated). Related do-
nor transplants were done at recipient mean age 7.8 yr vs unrelated
9.2 yr (p5 0.45). 68% of patients analyzed are currently alive, 18/44
(41%) alive at.1 yr from HSCT. GvHD was seen at the examined
timepoints in 23% (10/44) of patients overall, with 14% (6/44) hav-
ing AGvHD only, 11% (5/44) CGvHD only and 9% (4/44) experi-
encing both. No differences were found in occurrence of grade 2–4
AGvHD or extensive CGvHD at examined timepoints when com-
paring donors, except a trend toward more AGvHD at 100 days and
more CGvHD at latest F/U for related donors (see table). Conclu-
sion: It has been hypothesized that a RIC regimen will lead to less
recipient tissue damage with less inflammatory cytokine release and
may result in fewer toxicities and less GvHD. In pediatric RIC
HSCT we demonstrate a low prevalence of grade 2–4 acute and ex-
tensive chronic GvHD during a short F/U period, with no statisti-
cally significant differences between related and unrelated donor
stem cell sources. Future study with case-matched controls receiv-
ing TMC HSCT will help determine whether toxicity and GvHD
are reduced in RIC HSCT.208
THE USE, SAFETY, AND EFFICACY OF DACLIZUMAB FOR STEROID RE-
FRACTORY GRAFT-VERSUS-HOST-DISEASE (GVHD) AFTER UNRELATED
CORD BLOOD TRANSPLANTATION (UCBT)
Mohamed, A.1, Niedzwiecki, D.2, Baker, J.H.1, Vinesett, R.1,
Martin, P.L.1, Driscoll, T.A.1, Prasad, V.K.1, Parikh, S.1,
Kurtzberg, J.1, Szabolcs, P.1. 1Duke University, Durham, NC; 2Duke
University, Durham, NC.
UCBT is a life-saving form of hematopoietic cell transplantation
(HCT), however GVHD can hamper success. Steroid refractory
GVHD increases the incidence and severity of infections, leads to in-
creased mortality by 6 months. Daclizumab, a humanized anti-CD25
antibody has been widely utilized for treating GVHD after favorable
reports (Blood 1994;84:1320, Blood 2000;95:83). It’s efficacy and
safety, however, has been questioned by a recent multicenter, double
blinded, randomized trial (Blood;2004:104:1559) showing inferior
100-day and 1 year survival. The efficacy and safety of daclizumab af-
ter UCBT, however is not known. We report here the results of a ret-
rospective analysis on a cohort of three hundred twenty nine (329)
children who received a single UCB graft as first transplant between
1999 and 2005. All received myeloablative conditioning regimens,
ATG pre-UCBT and GvHD prophylaxis consisting of Cyclosporine
1Methylprednisolone (MPDN) or MMF (last 12 pts).
Results: Daclizumab was used to treat steroid refractory GVHD
in 89 patients (27%). 58 patients started therapy at a median of 36
days (mean 366 19) post-UCBT for acute GVHD, while 31 started
significantly later at a median of 207 days (mean 3866 452). Those
who received Daclizumab for acute GVHD (n5 58) were analyzed
and compared to the 239 patients who never received the drug (most
with grade 0-I GVHD). In univariate analysis, patients receiving
Daclizumab were significantly younger (mean 5.1 vs 6.9 years, p
5 0.03), less likely to have malignancy (p 5 0.001) and received
TBI (p 5 0.004). There were no differences in gender, ethnicity,
CMV serology, HLA-mismatch, TNC, CD31, and CD341 cell
dose/kg. OS at 6 months was comparable between these groups,
(57% versus 65% Chi-Square p 5 0.23). After 42 days of therapy,
response was scored based on IBMTR consensus criteria. 10 pa-
tients did not complete therapy due to death in 9; [relapse (3),
pre-existing infections (4), multiorgan failure (2)] Of those evalu-
able at D42, overall GVHD severity was downgraded in 35 of 46
(76%). MPDN was reduced from a mean of 2.0 mg/kg/day to
0.90 mg/kg/day by D42. Skin GVHD was downgraded to stage
0–1 in 45 of 46 patients. 11 patients with gut GVHD stages 2–4 im-
proved to stage 0–1 while 8 either failed to respond or worsened to
$stage 2. None of the three patients with liver GVHD (stages 3–4)
responded. Conclusion: Daclizumab therapy in UCBT recipients
appears safe with excellent response in skin but modest response
for visceral GVHD.
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UMBILICAL CORD BLOOD STEM CELL TRANSPLANTS FOR NONMALIG-
NANT HEMATOPOIETIC DISORDERS
Willert, J.1, Rosenthal, J.2, Brown, H.L.3, David, H.T.4. 1Rady Chilren’s
Hospital of San Diego, San Diego, CA; 2City of Hope, Duarte, CA; 3CBR
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